TY - JOUR T1 - Response to: ‘Tapering antirheumatic drugs in a resource-poor setting: real-world evidence’ by Haroon <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e209 LP - e209 DO - 10.1136/annrheumdis-2020-218731 VL - 81 IS - 10 AU - Elise van Mulligen AU - Pascal H P de Jong Y1 - 2022/10/01 UR - http://ard.bmj.com/content/81/10/e209.abstract N2 - We appreciate the interest in our paper by Haroon, et al. We presented the 2-year results of the TARA trial, in which we concluded that ‘financial arguments may influence the decision to taper tumour necrosis factor-inhibitors first’.1 Based on this conclusion, Haroon, et al decided to respond to that with their real-world data from a resource-poor country.2 Ideally, if patients with rheumatoid arthritis (RA) are in sustained remission, then medication is quickly tapered and possibly stopped to reduce healthcare costs. Disease modifying anti-rheumatic drug (DMARD)-free remission is suggested as a preferred ultimate target in a treat-to-target management approach; however, we previously showed, in a systematic literature review, that this outcome is achievable in … ER -